Novo Nordisk has launched Ozempic, its once-weekly semaglutide injection for adults with type 2 diabetes, in the Indian market. The GLP-1 therapy, already widely used globally, offers blood-sugar control along with clinically proven weight-loss benefits and protection against heart and kidney complications. The launch comes as India faces a growing diabetes and obesity burden, with doctors expected to consider Ozempic as a first-line treatment alongside diet and exercise.

See Full Page